Advertisement
Screener

OCULAR THERAPEUTIX, INC (OCUL) Graph

OCUL Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $13.47M; Cost of revenue $2.01M; Research and development $54.14M; Operating expenses (m).
  • 2026-03-31: Revenue $10.79M; Cost of revenue $1.33M; Research and development $66.21M; Operating expenses (m).
  • 2025-12-31: Revenue $13.25M*; Cost of revenue $1.59M*; Research and development $50.80M*; Operating expenses (m).
  • 2025-09-30: Revenue $14.54M; Cost of revenue $1.77M; Research and development $52.36M; Operating expenses (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OCUL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$13.48MRevenue$13.48MCost of revenue$2.01MOperating income-$82.11MResearch & development$54.14MNet income-$78.76M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OCUL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Single ReportableSegment$13.48MRevenue$13.48MCost of revenue$2.01MOperating income-$82.11MResearch & development$54.14MNet income-$78.76M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30$13.47M$2.01M$54.14M(m)-$78.76M
2026-03-31$10.79M$1.33M$66.21M(m)-$88.61M
2025-12-31$13.25M*$1.59M*$50.80M*(m)-$64.65M*
2025-09-30$14.54M$1.77M$52.36M(m)-$69.42M
2025-06-30$13.46M$1.94M$51.08M(m)-$67.81M
2025-03-31$10.70M$1.26M$42.86M(m)-$64.05M
2024-09-30$15.43M$1.56M$37.05M(m)-$36.49M
2024-06-30$16.44M$1.51M$28.86M(m)-$43.78M
2024-03-31$14.77M$1.33M$20.73M(m)-$64.85M
2023-09-30$15.08M$1.38M$15.02M(m)-$516.00K
2023-06-30$15.19M$1.30M$15.09M(m)-$20.68M
2023-03-31$13.37M$1.21M$14.75M(m)-$30.32M
2022-09-30$11.96M$1.07M$13.72M(m)-$24.19M
2022-06-30$12.27M$1.16M$13.10M(m)-$18.77M
2022-03-31$13.19M$1.30M$13.10M(m)-$12.54M
2021-09-30$12.15M$1.31M$12.72M(m)$2.66M
2021-06-30$11.72M$1.10M$13.86M(m)-$8.48M
2021-03-31$7.34M$892.00K$10.93M(m)$3.12M
2020-09-30$5.88M$450.00K$6.95M(m)-$11.94M
2020-06-30$1.57M$134.00K$8.02M(m)-$36.57M
2020-03-31$2.61M$819.00K$6.10M(m)-$21.51M
2019-12-31$2.26M(m)(m)(m)-$26.02M
2019-09-30$829.00K$806.00K$10.23M(m)-$18.78M
2019-06-30$650.00K$552.00K$9.41M(m)-$24.45M
2019-03-31$492.00K$128.00K$11.32M(m)-$17.12M
2018-12-31$504.00K(m)(m)(m)-$17.40M
2018-09-30$498.00K$115.00K$9.69M(m)-$15.01M
2018-06-30$648.00K$153.00K$8.74M(m)-$13.80M
2018-03-31$340.00K$80.00K$8.23M(m)-$13.77M
2017-12-31$487.00K(m)(m)(m)-$13.10M
2017-09-30$523.00K(m)$8.13M(m)-$15.57M
2017-06-30$438.00K(m)$8.12M(m)-$18.69M
2017-03-31$475.00K(m)$6.73M(m)-$16.02M
2016-12-31$511.00K(m)(m)(m)-$12.82M
2016-09-30$477.00K(m)$5.69M(m)-$9.60M
2016-06-30$441.00K(m)$6.98M(m)-$11.45M
2016-03-31$458.00K(m)$7.07M$10.97M-$10.84M
2015-12-31$436.00K(m)(m)$10.71M*-$10.64M
2015-09-30$429.00K(m)$8.26M$11.60M-$11.52M
2015-06-30$459.00K(m)$6.74M$10.09M-$10.01M
2015-03-31$426.00K(m)$4.72M$7.54M-$7.58M
2014-12-31$505.00K(m)(m)(m)-$7.95M
2014-09-30$143.00K(m)$4.48M$6.92M-$7.29M
2014-06-30$97.00K(m)$4.29M$6.04M-$6.39M
2014-03-31$27.00K(m)$4.96M$6.85M-$7.01M
2013-12-31(m)(m)(m)(m)-$3.50M
2013-09-30(m)(m)$2.78M$3.44M-$3.52M
2013-06-30(m)(m)$2.40M$2.99M-$3.09M
2013-03-31(m)(m)(m)(m)-$3.20M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30$24.26M$3.34M$120.35M(m)-$167.38M
2025-06-30$24.16M$3.21M$93.94M(m)-$131.87M
2024-06-30$31.21M$2.83M$49.59M(m)-$108.63M
2023-06-30$28.56M$2.52M$29.84M(m)-$51.00M
2022-06-30$25.45M$2.45M$26.20M(m)-$31.31M
2021-06-30$19.06M$1.99M$24.79M(m)-$5.36M
2020-06-30$4.18M$953.00K$14.12M(m)-$58.08M
2019-06-30$1.14M$680.00K$20.73M(m)-$41.58M
2018-06-30$988.00K$233.00K$16.97M(m)-$27.57M
2017-06-30$913.00K(m)$14.85M(m)-$34.72M
2016-06-30$899.00K(m)$14.05M(m)-$22.29M
2015-06-30$885.00K(m)$11.46M$17.63M-$17.59M
2014-06-30$124.00K(m)$9.25M$12.89M-$13.40M
2013-06-30(m)(m)$4.89M$6.05M-$6.29M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2025-09-30$38.70M$4.98M$146.30M(m)-$201.28M
2024-09-30$46.64M$4.40M$86.65M(m)-$145.12M
2023-09-30$43.64M$3.90M$44.86M(m)-$51.52M
2022-09-30$37.42M$3.53M$39.92M(m)-$55.50M
2021-09-30$31.21M$3.30M$37.51M(m)-$2.70M
2020-09-30$10.05M$1.40M$21.07M(m)-$70.02M
2019-09-30$1.97M$1.49M$30.97M(m)-$60.35M
2018-09-30$1.49M$348.00K$26.66M(m)-$42.58M
2017-09-30$1.44M(m)$22.97M(m)-$50.28M
2016-09-30$1.38M(m)$19.74M(m)-$31.88M
2015-09-30$1.31M(m)$19.73M$29.24M-$29.11M
2014-09-30$267.00K(m)$13.73M$19.81M-$20.69M
2013-09-30(m)(m)$7.67M$9.48M-$9.81M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$51.95M$6.57M$197.10M(m)$0.00-$265.94M
2024-12-31$63.72M$5.63M$127.64M(m)$0.00-$193.51M
2023-12-31$58.44M$5.28M$61.05M(m)$0.00-$80.74M
2022-12-31$51.49M$4.54M$53.46M(m)$0.00-$71.04M
2021-12-31$43.52M$4.41M$50.08M(m)$0.00-$6.55M
2020-12-31$17.40M$2.08M$28.69M(m)$0.00-$155.64M
2019-12-31$4.23M$2.33M$41.09M(m)$0.00-$86.37M
2018-12-31$1.99M$465.00K$36.91M(m)$0.00-$59.98M
2017-12-31$1.92M$457.00K$30.88M(m)$0.00-$63.39M
2016-12-31$1.89M(m)$27.07M(m)$0.00-$44.70M
2015-12-31$1.75M(m)$26.61M$39.95M$0.00-$39.75M
2014-12-31$772.00K(m)$18.88M$27.87M$0.00-$28.65M
2013-12-31(m)(m)$10.52M$12.90M$0.00-$13.32M
2012-12-31$10.00K(m)$11.54M$13.68M$0.00-$14.09M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Zai Lab Ltd (ZLAB)$2.241B-113.34
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05